India’s fight against diabetes just got a major boost. The Central Drugs Standard Control Organisation (CDSCO) has officially approved Ozempic for use in adults with type 2 diabetes, marking a significant milestone in the modern treatment of diabetes [1]. Semaglutide, the active ingredient in Ozempic, is now available in India – marking a new chapter in advanced, prescription-based diabetes care.
Not just diabetes, discover how semaglutide is changing the conversation around obesity. Read the full story here.
What Is Ozempic?
Ozempic is a weekly injectable medicine from the class of GLP-1 receptor agonists [2]. GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate appetite and blood sugar. Ozempic was first approved internationally for managing type 2 diabetes, where it helps by
- Stimulating insulin release when blood sugar levels are high
- Suppressing excess glucagon, a hormone that increases blood sugar secretion
- Slowing down stomach emptying helps reduce appetite and food intake.
Over time, clinical use revealed that many people using semaglutide also lost significant weight, prompting interest in weight management as well [3].
Regular check-ups are essential; Consult an expert for effective diabetes management.
Expanding Diabetes Care in India with Weekly GLP-1 Therapy
High Disease Burden, High Demand
Around 100 million people in India live with type 2 diabetes. [4]. For those who haven’t found success with conventional treatments, Ozempic offers a new, clinically backed option to manage blood sugar effectively.
Completing the Semaglutide Portfolio
With oral semaglutide already available and obesity-focused versions recently launched, Ozempic completes the range of semaglutide therapies in India.
Potential for Cardiovascular and Kidney Benefits
Beyond controlling blood sugar, global trials have shown that semaglutide can lower cardiovascular risks, improve kidney outcomes, and support weight management [6].
Stay on top of your blood sugar—book your comprehensive diabetes care package today.
What You Need To Know
Ozempic, a weekly injectable GLP-1 therapy for type 2 diabetes, is approved by CDSCO and will be available in India soon. MRP and launch details will be announced at the time of market release. Other things to keep in mind:
Suitability And Indications
Ozempic is indicated for type 2 diabetes management. While weight loss is a valued benefit, prescribing it for obesity without diabetes should only be done under your doctor’s careful evaluation, following clear guidelines.
Side Effects And Monitoring
Common side effects can include nausea, vomiting, and gastrointestinal discomfort. Less commonly, pancreatitis, gallbladder issues, or kidney changes may occur. Close monitoring, particularly early in therapy, is essential.
Safety Precautions
Ozempic should not be used by people with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2. It is also not recommended for people with severe gastrointestinal disease or a history of pancreatitis.
Lifestyle Remains Key
Ozempic is a powerful adjunct, but it’s not the complete picture. Diet, physical activity, sleep, and behavioural changes remain core elements to keep diabetes in check and manage metabolic health.
Control your blood sugar by managing your weight —start your personalized health plan today.
Final Thoughts
Ozempic’s launch in India marks a turning point. It brings a scientifically validated, globally tested therapy into local care settings — offering new options and hope for people with type 2 diabetes and those struggling with metabolic health. But the real impact will depend on responsible adoption, patient education, and continuous oversight.
If you’re a person considering this therapy, always discuss with your doctor to make an informed decision tailored to your medical history and goals. If you’re a clinician, this is not just a drug launch; it’s an opportunity to reimagine how we manage metabolic disease in India.
Frequently Asked Questions On Ozempic
-Will Ozempic cause low blood sugar (hypoglycemia)?
Ozempic rarely causes low blood sugar, but the risk increases if combined with other diabetes medications. Always follow your doctor’s instructions, and they will guide you through the necessary adjustments.
-How soon can I expect to see results?
Some people notice improved blood sugar within a few weeks, while weight changes may take a few months; progress varies from person to person.
-Can Ozempic help me lose weight even if I don’t have diabetes?
Ozempic is primarily used to manage type 2 diabetes, but many people may also experience weight loss as an added benefit. Your doctor can advise if it’s appropriate for your weight management goals.
-Do I need to change my diet while on Ozempic?
Yes. Ozempic works best with balanced meals, regular activity, and healthy lifestyle choices to support both blood sugar and weight goals.
Check in with an expert to see if Ozempic fits your health plan today.
Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Please consult your doctor for personalized guidance.
References:
[1] ANI News. CDSCO approves Novo Nordisk’s injection for type 2 diabetes patients. Available from: https://www.aninews.in/news/national/general-news/cdsco-approves-danish-drugmaker-novo-nordisks-injection-for-type-2-diabetes-patients20250930203309/?amp=1
[2] U.S. Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
[3] National Center for Biotechnology Information. Semaglutide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
[3] Wharton S, Lingvay I, Davies M, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(6):401-410. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00226-8/fulltext
[4] Aroda V, Mehta A, Buse J, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER clinical trial programmes. Diabetes Obes Metab. 2023;25(6):1505-1513. Available from: https://pubmed.ncbi.nlm.nih.gov/36700417/
(The article is written by Dr. Syeda Aafia, Team Lead and reviewed by Dr. Swati Mishra, Director, Clinical Health & Content, Medical Affairs)